vijoice Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vijoice, and when can generic versions of Vijoice launch?
Vijoice is a drug marketed by Novartis and is included in two NDAs. There are two patents protecting this drug.
This drug has fifty-eight patent family members in forty-eight countries.
The generic ingredient in VIJOICE is alpelisib. One supplier is listed for this compound. Additional details are available on the alpelisib profile page.
DrugPatentWatch® Generic Entry Outlook for Vijoice
Vijoice was eligible for patent challenges on May 24, 2023.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 29, 2033. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for vijoice?
- What are the global sales for vijoice?
- What is Average Wholesale Price for vijoice?
Summary for vijoice
| International Patents: | 58 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 74 |
| Clinical Trials: | 2 |
| Patent Applications: | 830 |
| Drug Prices: | Drug price information for vijoice |
| What excipients (inactive ingredients) are in vijoice? | vijoice excipients list |
| DailyMed Link: | vijoice at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for vijoice
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for vijoice
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Celcuity, Inc. | Phase 3 |
US Patents and Regulatory Information for vijoice
vijoice is protected by two US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of vijoice is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting vijoice
Pyrrolidine-1,2-dicarboxamide derivatives
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pyrrolidine-1,2-dicarboxamide derivatives
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting vijoice
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH SEVERE MANIFESTATIONS OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) WHO REQUIRE SYSTEMIC THERAPY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | VIJOICE | alpelisib | GRANULES;ORAL | 218466-001 | Apr 24, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Novartis | VIJOICE | alpelisib | TABLET;ORAL | 215039-002 | Apr 5, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Novartis | VIJOICE | alpelisib | TABLET;ORAL | 215039-001 | Apr 5, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Novartis | VIJOICE | alpelisib | TABLET;ORAL | 215039-003 | Apr 5, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Novartis | VIJOICE | alpelisib | TABLET;ORAL | 215039-002 | Apr 5, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Novartis | VIJOICE | alpelisib | TABLET;ORAL | 215039-003 | Apr 5, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for vijoice
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Novartis Europharm Limited | Piqray | alpelisib | EMEA/H/C/004804 Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1). |
Authorised | no | no | no | 2020-07-27 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for vijoice
When does loss-of-exclusivity occur for vijoice?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 3369
Patent: DERIVADOS DE 2-CARBOXAMIDA-CICLOAMINO-UREA COMO INHIBIDORES DE PI-3
Estimated Expiration: ⤷ Sign Up
Patent: 2074
Patent: DERIVADOS DE 2-CARBOXAMIDA-CICLOAMINO-UREA COMO INHIBIDORES DE PI-3
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 09290904
Patent: Organic compounds
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0918750
Patent: compostos orgânicos
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 34819
Patent: COMPOSES ORGANIQUES (ORGANIC COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 11000504
Patent: Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
Estimated Expiration: ⤷ Sign Up
China
Patent: 2149711
Patent: Organic compounds
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 51738
Patent: COMPUESTOS ORGANICOS
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 110059
Patent: COMPUESTOS ORGANICOS
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0160014
Estimated Expiration: ⤷ Sign Up
Cuba
Patent: 000
Patent: UN DERIVADO 2-CARBOXAMIDA-CICLOAMINO-UREA-TIAZOL-PIRIDILO
Estimated Expiration: ⤷ Sign Up
Patent: 110052
Patent: COMPUESTOS ORGÁNICOS
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 17078
Estimated Expiration: ⤷ Sign Up
Patent: 20037
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 31537
Estimated Expiration: ⤷ Sign Up
Dominican Republic
Patent: 011000070
Patent: COMPUESTOS ORGANICOS
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 11010880
Patent: COMPUESTOS ORGÁNICOS
Estimated Expiration: ⤷ Sign Up
El Salvador
Patent: 11003853
Patent: COMPUESTOS ORGANICOS
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 8863
Patent: ОРГАНИЧЕСКИЕ СОЕДИНЕНИЯ (ORGANIC COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 1100447
Patent: ОРГАНИЧЕСКИЕ СОЕДИНЕНИЯ
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 31537
Patent: DÉRIVÉS DE 1-((5-HÉTÉROARYLTHIAZOL-2-YL)AMINOCARBONYL)PYRROLIDINE-2-CARBOXAMIDE COMME INHIBITEURS DE PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) UTILES DANS LE TRAITEMENT DE MALADIES PROLIFÉRATIVES (1-((5-HETEROARYLTHIAZOL-2-YL)AMINOCARBONYL)PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES)
Estimated Expiration: ⤷ Sign Up
Georgia, Republic of
Patent: 0135991
Patent: 2-CARBOXAMIDE-PYRROLIDINE-AMIDE UREA DERIVATIVES SUBSTITUTED WITH PYRIMIDINE-4-YL, AND USAGE THEREAT TREATMENT OF DISEASES CAUSED BY PHOSPHATIDYL INOSITOL 3-KINASE
Estimated Expiration: ⤷ Sign Up
Honduras
Patent: 11000699
Patent: EL COMPUESTO (S)-1-({4-METIL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETIL-ETIL)-PIRIDIN-4-IL]-TIAZOL-2-IL}-AMIDA) DE 2-AMIDA DEL ACIDO PIRROLIDIN-1,2-DICARBOXILICO EN FORMA LIBRE O DE SAL Y COMPOSICIONES Y COMPOSICION FARMACEUTICA QUE LO CONTIENE.
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 56305
Patent: 作為磷脂醯肌醇- 肌酵素 抑制物而有用於治療增生性疾病之 -羧酸基- -雜芳基噻唑- -基 氨基羰基 吡咯烷衍生物 (1-((5-HETEROARYLTHIAZOL-2-YL)AMINOCARBONYL)PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES -3 (PI3K) 2--1-((5- -2-)))
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 25884
Estimated Expiration: ⤷ Sign Up
Patent: 000044
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 0976
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 86601
Estimated Expiration: ⤷ Sign Up
Patent: 12502080
Estimated Expiration: ⤷ Sign Up
Jordan
Patent: 21
Patent: مشتقات 1 - ((5-هيتيرورلثيازول-2-يل) أمينوكاربونيل) بيروليدين-2-كربوكساميد كمثبات الفوسفاتديلينوسيتول 3-كيناس (PI3K) مفيدة في علاج الأمراض التصاعدية (1-((5-HETEROARYLTHIAZOL-2-YL)AMINOCARBONYL)PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 331537
Estimated Expiration: ⤷ Sign Up
Patent: 2020534
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 1556
Patent: ORGANIC COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 11002597
Patent: COMPUESTOS ORGANICOS. (ORGANIC COMPOUNDS.)
Estimated Expiration: ⤷ Sign Up
Montenegro
Patent: 284
Patent: ORGANSKA JEDINJENJA (ORGANIC COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 604
Patent: مركبات عضوية
Estimated Expiration: ⤷ Sign Up
Netherlands
Patent: 1071
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 0754
Patent: Pyridin-4-yl substituted 2-carboxamide pyrrolidine-amide urea derivatives and their use in the treatment of phosphatidylinositol 3-kinase mediated diseases
Estimated Expiration: ⤷ Sign Up
Nicaragua
Patent: 1100049
Patent: COMPUESTOS ORGÁNICOS.
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 20037
Estimated Expiration: ⤷ Sign Up
Panama
Patent: 41901
Patent: COMPUESTOS ORGÁNICOS
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 110796
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 31537
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 31537
Estimated Expiration: ⤷ Sign Up
San Marino
Patent: 201100019
Patent: Composti organici.
Estimated Expiration: ⤷ Sign Up
Patent: 01100019
Patent: Composti organici
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 476
Patent: DERIVATI 1-((5-HETEROARILTIAZOL-2-IL)AMINOKARBONIL)PIROLIDIN-2-KARBOKSAMIDA KAO INHIBITORI FOSFATIDILINOZITOL 3-KINAZE (PI3K) KORISNI U TRETMANU PROLIFERATIVNIH OBOLJENJA (1-((5-HETEROARYLTHIAZOL-2-YL)AMINOCARBONYL)PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES)
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 31537
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1100699
Patent: ORGANIC COMPOUNDS
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1290844
Estimated Expiration: ⤷ Sign Up
Patent: 110038737
Patent: ORGANIC COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 60673
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 53206
Estimated Expiration: ⤷ Sign Up
Patent: 1014851
Patent: Organic compounds
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 11000053
Patent: ORGANIC COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 4147
Patent: ПРОИЗВОДНАЯ ПИРРОЛИДИНДИКАРБОНОВОЙ КИСЛОТЫ И ЕЕ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ;ПОХІДНА ПІРОЛІДИНДИКАРБОНОВОЇ КИСЛОТИ ТА ЇЇ ЗАСТОСУВАННЯ У ЛІКУВАННІ ПРОЛІФЕРАТИВНИХ ЗАХВОРЮВАНЬ (PYRROLIDINE DICARBOXYLIC ACID DERIVATIVE AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISEASES)
Estimated Expiration: ⤷ Sign Up
Uruguay
Patent: 096
Patent: DERIVADOS DE 2-CARBOXAMIDA - CICLOAMINO - UREA ESPECÌFICOS, SUS SALES FARMACÈUTICAMENTE ACEPTABLES, COMPOSICIONES CONTENIÈNDOLOS, PRO-FARMACOS DE LOS MISMOS, PROCESOS PARA SU PRODUCIÒN Y APLICACIONES
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering vijoice around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Taiwan | I453206 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 2010029082 | ⤷ Sign Up | |
| Spain | 2560673 | ⤷ Sign Up | |
| Tunisia | 2011000053 | ORGANIC COMPOUNDS | ⤷ Sign Up |
| Jordan | 3121 | مشتقات 1 - ((5-هيتيرورلثيازول-2-يل) أمينوكاربونيل) بيروليدين-2-كربوكساميد كمثبات الفوسفاتديلينوسيتول 3-كيناس (PI3K) مفيدة في علاج الأمراض التصاعدية (1-((5-HETEROARYLTHIAZOL-2-YL)AMINOCARBONYL)PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES) | ⤷ Sign Up |
| Mexico | 2011002597 | COMPUESTOS ORGANICOS. (ORGANIC COMPOUNDS.) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for vijoice
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2331537 | 122020000073 | Germany | ⤷ Sign Up | PRODUCT NAME: ALPELISIB ODER EIN PHARMAZEUTISCH ZULAESSIGES SALZ DAVON; NAT. REGISTRATION NO/DATE: EU/1/20/1455 20200727; FIRST REGISTRATION: SCHWEIZ 67359 20200324 |
| 2331537 | 47/2020 | Austria | ⤷ Sign Up | PRODUCT NAME: ALPELISIB ODER SALZ DAVON; NAT. REGISTRATION NO/DATE: EU/1/20/1455 (MITTEILUNG) 20200728; FIRST REGISTRATION: CH 67359 20200324 |
| 2331537 | 2020037 | Norway | ⤷ Sign Up | PRODUCT NAME: ALPELISIB ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV; REG. NO/DATE: EU/1/20/1455 20200810 |
| 2331537 | CR 2020 00054 | Denmark | ⤷ Sign Up | PRODUCT NAME: ALPELISIB ELLER ET FARMACEUTISK ACCEPTABELT SALT HERAF; NAT. REG. NO/DATE: EU/1/20/1455 20200728; FIRST REG. NO/DATE: CH 67359 20200324 |
| 2331537 | PA2020534 | Lithuania | ⤷ Sign Up | PRODUCT NAME: ALPELISIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/20/1455 20200727 |
| 2331537 | CA 2020 00054 | Denmark | ⤷ Sign Up | PRODUCT NAME: ALPELISIB ELLER ET FARMACEUTISK ACCEPTABELT SALT HERAF; REG. NO/DATE: EU/1/20/1455 20200728 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
